Raise the bar even higher for primary prevention interventions

Archives of Internal Medicine

Volumn 172, Issue 17, 2012, Pages 1352-1353

  Wright, James M ^a   Bassett, Ken L ^a   Tejani, Aaron M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADVERSE OUTCOME; CLINICAL EFFECTIVENESS; HOSPITALIZATION; HUMAN; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; NOTE; PREVENTIVE HEALTH SERVICE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CARDIOVASCULAR DISEASES; CAUSE OF DEATH; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRIMARY PREVENTION;

EID: 84867166488     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.3723     Document Type: Note

References (4)

1. Prasad V, Vandross A. Cardiovascular primary prevention: how high should we set the bar? Arch Intern Med. 2012;172(8):656-659.
2. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: guideline for good clinical practice E6(R1). June 10, 1996. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E6-R1/Step4/E6-R1-Guideline.pdf. Accessed April 25, 2012.
3. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010;170(12):1024-1031.
4. Therapeutics Initiative. Do statins have a role in primary prevention? an update. Therapeutics Letter. March-April 2010;(77). http://www.ti.ubc.ca/ letter77. Accessed December 12, 2011.